Cargando…

Dual intracellular targeting by ruxolitinib and the Mcl-1 inhibitor S63845 in interleukin-6-dependent myeloma cells blocks in vivo tumor growth

Detalles Bibliográficos
Autores principales:	Burger, Renate, Otte, Anna, Brdon, Jan, Peipp, Matthias, Gramatzki, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2021
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409037/ https://www.ncbi.nlm.nih.gov/pubmed/33882638 http://dx.doi.org/10.3324/haematol.2020.276865

Ejemplares similares

MCL-1 Inhibitor S63845 Distinctively Affects Intramedullary and Extramedullary Hematopoiesis
por: Zhang, Hexiao, et al.
Publicado: (2023)

Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer
por: Liu, Dongyan, et al.
Publicado: (2021)

Correction: Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer
por: Liu, Dongyan, et al.
Publicado: (2021)

MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells
por: Mukherjee, Nabanita, et al.
Publicado: (2020)

Combination of tyrosine kinase inhibitors and the MCL1 inhibitor S63845 exerts synergistic antitumorigenic effects on CML cells
por: Malyukova, Alena, et al.
Publicado: (2021)

Sensitivity of Cutaneous T-Cell Lymphoma Cells to the Mcl-1 Inhibitor S63845 Correlates with the Lack of Bcl-w Expression
por: Sumarni, Uly, et al.
Publicado: (2022)

A novel Fc-engineered human ICAM-1/CD54 antibody with potent anti-myeloma activity developed by cellular panning of phage display libraries
por: Klausz, Katja, et al.
Publicado: (2017)

Pharmaceutical Drug Metformin and MCL1 Inhibitor S63845 Exhibit Anticancer Activity in Myeloid Leukemia Cells via Redox Remodeling
por: Valiulienė, Giedrė, et al.
Publicado: (2021)

BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia
por: Seipel, Katja, et al.
Publicado: (2021)

The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells
por: Li, Zhaodong, et al.
Publicado: (2018)

Fc-engineering significantly improves the recruitment of immune effector cells by anti-ICAM-1 antibody MSH-TP15 for myeloma therapy
por: Klausz, Katja, et al.
Publicado: (2020)

Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma
por: Algarín, Esperanza M., et al.
Publicado: (2021)

The novel immunotoxin HM1.24-ETA′ induces apoptosis in multiple myeloma cells
por: Staudinger, M, et al.
Publicado: (2014)

Promoting natural killer cell functions by recombinant immunoligands mimicking an induced self phenotype
por: Kellner, Christian, et al.
Publicado: (2013)

Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia
por: Seipel, Katja, et al.
Publicado: (2021)

Perspectives of Fc engineered antibodies in CD19 targeting immunotherapies in pediatric B-cell precursor acute lymphoblastic leukemia
por: Kellner, Christian, et al.
Publicado: (2018)

Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma
por: Al-Odat, Omar S., et al.
Publicado: (2021)

Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes
por: Seiller, Carolane, et al.
Publicado: (2020)

Gossypol induces apoptosis in multiple myeloma cells by inhibition of interleukin-6 signaling and Bcl-2/Mcl-1 pathway
por: SADAHIRA, KEN, et al.
Publicado: (2014)

Myeloid Cell Leukemia 1 Small Molecule Inhibitor S63845 Synergizes with Cisplatin in Triple-Negative Breast Cancer
por: Acton, Alexus, et al.
Publicado: (2023)

Ruxolitinib induces apoptosis of human colorectal cancer cells by downregulating the JAK1/2-STAT1-Mcl-1 axis
por: Li, Xia, et al.
Publicado: (2021)

Erratum: Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma
Publicado: (2021)

HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity
por: Peipp, Matthias, et al.
Publicado: (2015)

Ruxolitinib Cream Has Dual Efficacy on Pruritus and Inflammation in Experimental Dermatitis
por: Scuron, Monika D., et al.
Publicado: (2021)

STAT3-induced long noncoding RNAs in multiple myeloma cells display different properties in cancer
por: Binder, Stefanie, et al.
Publicado: (2017)

Ruxolitinib for myelofibrosis
por: GU, LIAN, et al.
Publicado: (2013)

Venetoclax, alone and in combination with the BH3 mimetic S63845, depletes HIV-1 latently infected cells and delays rebound in humanized mice
por: Arandjelovic, Philip, et al.
Publicado: (2023)

Ruxolitinib: Thrombocytopenia following compassionate use of ruxolitinib: 2 case reports
Publicado: (2022)

Paradoxical activation of chronic lymphocytic leukemia cells by ruxolitinib in vitro and in vivo
por: Spaner, David E., et al.
Publicado: (2023)

Enhanced ADCC Activity of Affinity Maturated and Fc-Engineered Mini-Antibodies Directed against the AML Stem Cell Antigen CD96
por: Mohseni Nodehi, Sahar, et al.
Publicado: (2012)

The intracellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to, those of Bcl-2
Publicado: (1995)

Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells
por: De Veirman, Kim, et al.
Publicado: (2015)

Silence of MCL-1 upstream signaling by shRNA abrogates multiple myeloma growth
por: Wang, Mengchang, et al.
Publicado: (2014)

Ruxolitinib for essential thrombocythemia?
por: Bose, Prithviraj, et al.
Publicado: (2017)

Monitoring Circulating γδ T Cells in Cancer Patients to Optimize γδ T Cell-Based Immunotherapy
por: Oberg, Hans-Heinrich, et al.
Publicado: (2014)

Tribody [(HER2)(2)xCD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells
por: Oberg, Hans H., et al.
Publicado: (2018)

Intracellular BAPTA directly inhibits PFKFB3, thereby impeding mTORC1-driven Mcl-1 translation and killing MCL-1-addicted cancer cells
por: Sneyers, Flore, et al.
Publicado: (2023)

Targeting the apoptotic Mcl-1-PUMA interface with a dual-acting compound
por: Liu, Jiyuan, et al.
Publicado: (2017)

Ruxolitinib in Myelofibrosis and Polycythemia Vera
por: Wolfe, Leah
Publicado: (2016)

Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor
por: Manduzio, Palma
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_bnjpc8c80tjd0e0tbic58kbijh